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Abstract: 7,8-Dihydroxy-3-methyl-isochromanone-4 (XJP), is a polyphenolic natural 
product with moderate antihypertensive activity. To obtain new agents with stronger 
potency and safer profile, we employed XJP and naftopidil as the lead compounds to 
design and synthesize a novel class of hybrids as antihypertensive candidates, In the 
present study, a series of hybrids (6a-r) of XJP bearing arylpiperazine moiety, which is 
identified as the pharmacophore of naftopidil, were designed and synthesized as novel 
α1-adrenergic receptor antagonists. The biological evaluation showed that target 
compounds 6c, 6e, 6f, 6g, 6h, 6m and 6q possessed potent in vitro vasodilation potency 
and α1-adrenergic receptor antagonistic activity. Furthermore, the most potent 
compound 6e significantly reduced the systolic and diastolic blood pressure in 
spontaneously hypertensive rats (SHRs),which was comparable to that of naftopidil, 
and it had no observable effects on the basal heart rate, suggesting that 6e deserves to 
be further investigated as a potential clinical candidate for the treatment of hypertension. 
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1. Introduction 
 
Hypertension has become one of the most prevalent health issues in 21st century. Long 
term high blood pressure is a major risk factor for coronary artery disease, stroke, heart 
failure, and other cardiovascular diseases1,2. The conventional treatment of 
hypertension involves combination of drugs including angiotensin II receptor 
antagonists, calcium channel blockers, angiotensin-converting enzyme inhibitors 
(ACEI), α1-adrenergic receptor antagonists, β-adrenergic receptor blockers, diuretics, 
etc3,4,5,6. Despite various drugs have been applied in clinic for the treatment of 
hypertension, effective blood pressure control remains a major medical challenge and 
there has been a consistent demand for more effective and safer antihypertensive 
drugs7,8. Hence, development of new drugs with multiple actions could be of great 
significance for the treatment of hypertension. 
 
(±)-7,8-Dihydroxy-3-methyl-isochromanone-4[(±)-XJP, Figure 1, 1], isolated from the 
banana (Musasapientum L.) peel extract, is a structurally unique polyphenolic 
compound with multiple biological activities including antioxidative, antihypertensive 
and cardioprotective activities9,10. Particularly, in our previous studies, (±)-XJP 
exhibited moderate antihypertensive activity in a dose-dependent manner, the 
maximum antihypertensive effect of (±)-XJP at the dose of 100 mg/kg was comparable 
to that of captopril at the dose of 25 mg/kg in renal hypertensive rats (RHRs)11. In the 
further structural modification of (±)-XJP, some analogues (Figure 1, 2-4) were found 
to be more potent than (±)-XJP in spontaneously hypertensive rats (SHRs)12. 
 
α1-Adrenergic receptor antagonists have been used for the treatment of hypertension 
since 1976 as the introduction of prazosin, followed by the development of various α1-
adrenergic receptor antagonists, such as tamsulosin, terazosin, naftopidil13. Naftopidil 
is an α1-adrenergic receptor antagonist, which was marketed in Japan since 1999, acting 
by relaxation of vascular smooth muscle14. A widely accepted model of adrenergic 
ligands provides the presence of an arylpiperazine moiety, a linker and a heterocycle 
system (Figure 1). Many studies have highlighted the arylpiperazine moiety as the key 
pharmacophore of α1-adrenergic receptor antagonists, which consists a positive 
ionizable pharmacophore features. Besides, the isopropoxy moiety has also revealed a 
key feature of α1-adrenergic receptor antagonist as a hydrogen bond receptor15. 
 
Based on the reported model of α1-adrenergic receptor antagonist and our previous 
studies about XJP16, we envisioned the hybrids of naftopidil and XJP would be potent 
antihypertensive hybrids with α1-adrenergic receptor antagonistic activity and 
cardioprotective activities. Thus, as shown in Figure 1, the hybrids 6a-r were designed 
by replacing the naphthalene moiety of naftopidil with naturally occurring heterocycle 
isochromanone-4-one (XJP). The group linked to the piperazine nucleus was explored 
by introducing substituted aryl and alkyl while the key positive ionizable center and 
hydrogen bond acceptor were reserved. 
 
Herein, we reported the design, synthesis and pharmacological profile of a series of 
novel hybrids of XJP and naftopidil as antihypertensive candidates. Their vasodilation 
potency and α1-adrenergic receptor antagonistic activity in vitro were evaluated. 
Furthermore, the in vivo antihypertensive evaluation of the most potent compound 6e 
was performed in SHRs. 
 
Figure 1. Strategy for the design of isochroman-4-one hybrids bearing piperazine 
moiety as antihypertensive agents. 
 
2. Result and discussion 
2.1 Chemistry 
The traditional methods for the preparation of 4-isochroman-ones often suffered from 
limitations such as low yields, multi-step reactions or expensive metal catalysts15. An 
efficient synthesis of 4-isochroman-ones via Parham-type cyclization with Weinreb 
amide was developed by our group previously17. As shown in Scheme 1, the free 
phenolic hydroxyl groups of 7a-c were protected by benzyl group in quantitative yields, 
followed by reduction with sodium borohydride to provide alcohol 9a-c. Subsequent 
condensation with ethyl 2-bromopropionate in the presence of NaH afforded esters, 
which were hydrolyzed to get the acids 10a-c. The key intermediates 11a-c bearing 
Weinreb amide were prepared by alkylation with the N, O-dimethylhydroxylamine in 
75-80% yields. The annulation proceeded smoothly by adding t-BuLi at -78 oC within 
1 min to afford the isochroman-ones 12a-c in 90-93% yields, which were then 
converted to the analogues of XJP (2-4) via a deprotection operation with Pd/C.  
 
The synthetic route of the target compounds 6a-r was depicted in Scheme 2. 
Compounds 2-4 were treated with epichlorohydrin in the presence of potassium 
carbonate to give corresponding epoxides 13-15. Subsequent ring opening of the 
epoxides with various substituted piperazines afforded the target compounds 6a-r in 
60-80% yields. 
 
Scheme 1 Reagents and conditions: (a) K2CO3, benzyl bromide, DMF, 60oC, overnight; (b) NaBH4, 
MeOH, rt, 30 min, 93-96% yields; (c) 1) Ethyl 2-bromopropionate, NaH, rt, dry DMF; 2) NaOH, 
MeOH/H2O, reflux, 30 min; (d) Oxalyl chloride, then N, O-Dimethylhydroxylamine hydrochloride, 
75-80% yields; (e) t-BuLi, -78 oC, 1 min, then H2O, 90-93% yields; (f) Pd-C/H2, THF, rt, 4 h, 64-
72% yields. 
Scheme 2 Reagents and conditions: (a) anhydrous acetone, epichlorohydrin, K2CO3, reflux, 75–82% 
yield; (b) Zn(ClO4)2, DCM, 80oC, 15 min, 60-80% yield. 
 
2.2. Pharmacological evaluation 
2.2.1. In vitro antihypotensive activities  
Noradrenaline (NA)-induced isolated thoracic aorta ring was used to evaluate the in 
vitro antihypotensive effect of synthetic hybrids18. As shown in Table 1, the 
vasodilation potency of target compounds 6a-r at concentrations of 10 and 100µM was 
preliminarilyobtained in an organ bath system. The most potent compound 6e exhibited 
the similar vasodilation activity compared with positive control naftopidil. The analysis 
of structure-activity relationship suggested that the substituted position of linker has 
influence on the vasodilation potency. Generally, compounds bearing substitutions at 
C8-position were more potent than corresponding analogues bearing substitutions at 
C6- and C7-positions. Interestingly, the tetrahydrofuran group was more favorable as 
the substitution linked to the piperazine moiety, while furan was unfavorable. Besides, 
the substituents on the phenyl group also affected the vasodilation potency, such as 
compounds 6m vs 6p.  
 
Table 1. The effects of target compounds on NA-induced contractions in isolated 
thoracic aorta rings. 
 
Compounds 
Inhibition rate (%)  
Compounds 
Inhibition rate (%) 
10 µM 100 µM 10 µM 100 µM 
6a 28.59 ± 8.06 46.35 ± 18.56 6k 33.91 ± 26.63 40.12 ± 27.35 
6b 23.15 ± 10.80 44.63 ± 10.40 6l 17.83 ± 7.42 22.80 ± 10.64 
6c 25.35 ± 7.55 55.27 ± 17.64 6m 37.83 ± 11.34 59.72 ± 17.51 
6d 30.16 ± 13.87 42.41 ± 16.15 6n 13.58 ± 6.35 24.35 ± 7.04 
6e 41.59 ± 6.27 64.04 ± 11.60 6o 23.10 ± 12.36 36.08 ± 14.84 
6f 33.35 ± 15.35 44.86 ± 14.32 6p 18.21 ± 5.39 29.06 ± 11.64 
6g 39.20 ± 11.59 48.13 ± 16.62 6q 31.36 ± 7.10 45.11 ± 12.79 
6h 41.67 ± 11.79 50.35 ± 7.50 6r 20.81 ± 13.33 31.91 ± 14.43 
6i 11.62 ± 7.26 23.32 ± 13.27 Naftopidil 47.53 ± 16.81 65.15 ± 11.05 
6j 27.01 ± 7.04 32.43 ± 12.31 DMSO 16.88 ± 7.63 20.16 ± 9.67 
 
2.2.2. Evaluating pA2 values of representative compounds 
Representative compounds with good vasodilation potency were selected to test their 
α1-adrenergic receptor antagonistic activity relative to phenylephrine-reduced 
contractions. Antagonist efficacies were expressed as pA2 values calculated according 
to: pA2= -log[B] + log (r-1), where [B] is concentration of test compound and r is the 
ratio of concentrations of agonist required to generate 50% maximal response in the 
presence and absence of test compound. As shown in Table 2, the vasodilation potency 
of these compounds correlated well with their α1-adrenergic receptor antagonistic 
activity. The α1-adrenergic receptor antagonistic activity of compound 6e (pA2= 6.724) 
is comparable to that of naftopidil (pA2= 6.884). 
 
 
 
 
 
Table 2. Antagonist affinities of representative compounds, expressed as pA2 values on 
isolated ratthoracic aorta rings. 
Compounds pA2± SEM (Slope ± SEM) 
6c 6.314 ± 0.13 0.86 ± 0.03 
6e 6.724 ± 0.18 0.81 ± 0.05 
6f 5.811 ± 0.17 1.2 ± 0.06 
6g 6.207 ± 0.17 0.99 ± 0.04 
6h 5.658 ± 0.16 0.87 ± 0.03 
6m 6.528 ± 0.19 1.1 ± 0.05 
6q 6.469 ± 0.11 0.94 ± 0.03 
Naftopidil 6.844 ± 0.09 0.88 ± 0.02 
 
2.2.3. In vivo antihypertensive activity of compound 6e 
Based on the results of vasodilation potency of target compounds, the in vivo 
antihypertensive evaluation of the most potent compound 6e was performed in SHRs. 
After oral administration of the positive control naftopidil (80 mg/kg), and compound 
6e (80 mg/kg), the blood pressure and the heart rate of SHRs were detected from 0-8 h. 
Compound 6e significantly reduced the systolic and diastolic blood pressure in SHRs 
throughout the observation period (Fig. 2a and 2b), and have no observable effects on 
the basal heart rate (Fig. 2d). The mean arterial pressure (MAP) of SHRs treat with 6e 
was reduced by almost 23.7% at 4h, which was superior to that of naftopidil (16.1%) at 
2h (Fig. 2c), suggesting that compound 6e may possess better cardioprotective effects 
than naftopidil. 
 
Table 3. Effects of compound 6e on blood pressure in SHRsa 
Groups Parameter 
Time 
0 h 1 h 2 h 4 h 6 h 8 h 
Control 
SAP (mmHg) 186.10 ± 4.55b 185.35 ± 10.30 189.20 ± 12.31 178.66 ± 17.18 179.36 ± 18.33 179.42 ± 13.70 
DAP (mmHg) 149.50 ± 5.4 147.33 ± 9.8 149.90 ± 6.0 136.12 ± 5.3 137.54 ± 9.2 140.61 ± 10.3 
MAP(mmHg) 161.70 ± 5.12 160.00 ± 9.97 163.00 ± 8.10 150.30 ± 9.26 151.48 ± 12.24 153.55 ± 11.43 
HR (BPM) 413.17 ± 10.5 415.25 ± 14.7 413.20 ± 15.2 410.80 ± 17.4 411.12 ± 19.1 412.77 ± 11.3 
NAF 
SAP (mmHg) 181.92 ± 15.8 161.36 ± 13.4 148.13 ± 10.5** 153.65 ± 14.2** 158.22 ± 13.7* 170.50 ± 16.4 
DAP (mmHg) 152.14 ± 12.4 140.19 ± 10.3 129.85 ± 10.1** 134.31 ± 9.6** 139.57 ± 8.5 143.06 ± 10.2 
MAP(mmHg) 162.07 ± 13.53 147.25 ± 11.33 135.94 ± 10.23** 140.76 ± 11.13** 145.79 ±10.23 152.21 ±12.27 
HR (BPM) 415.15 ± 13.1 412.14 ± 17.2 406.12 ± 11.5 409.22 ± 16.4 411.19 ± 14.1 417.25 ± 18.6 
6e 
SAP (mmHg) 187.64 ± 22.3 169.21 ± 20.9* 150.80 ± 16.3** 140.29 ± 11.4** 157.46 ± 15.6* 170.38 ± 17.0 
DAP (mmHg) 156.23 ± 10.1 144.15 ± 13.6 131.86 ± 12.0** 120.54 ± 10.1** 132.51 ± 11.5* 141.89 ± 12.0 
MAP(mmHg) 166.70 ± 14.17 152.50 ± 16.03 138.17 ± 13.43** 127.12 ± 10.53**  140.83 ± 12.87* 151.39 ± 13.67 
HR (BPM) 415.33 ± 16.6 409.30 ± 12.3 408.14 ± 14.9 405.15 ± 20.2 411.01 ± 18.0 413.16 ± 13.7 
a SAP: systolic arterial pressure; DAP: diastolic arterial pressure; MAP: mean arterial pressure; HR: heart 
rate.  
bData are expressed as mean ± SEM (n=8) , *P< 0.1, **p< 0.05 as compared with the respective control. 
 
 
Figure 2. The acute antihypertensive activity of compound 6e in SHRs. (a) SAP：
systolicarterial pressure；(b) DAP：diastolic arterial pressure；(c) MAP:mean arterial 
pressure; (d) HR： heart rate. Data are presented as mean ±  SEM, n = 8. 
Significanceindicated by: *P < 0.05, **P < 0.01, versus control. 
 
3. Conclusions 
 In conclusion, based on our previous studies about the antihypertensive properties of 
XJP, a series of hybrids (6a-r) of XJP and α1-adrenergic receptor antagonist naftopidil 
were designed and synthesized to obtain new agents with stronger antihypertensive 
potency and safer profile. These novel hybrids bearing isochroman-4-one and 
arylpiperazine moieties exhibited moderate to good activities. Compounds 6c, 6e, 6f, 
6g, 6h, 6m and 6q, which have potent in vitro vasodilation potency, also exhibited good 
α1-adrenergic receptor antagonistic activity. Furthermore, the most potent compound 6e 
significantly reduced the systolic and diastolic blood pressure in SHRs and have no 
observable effects on the basal heart rate, which was comparable to that of naftopidil. 
The improved activities of these hybrid molecules qualified them as promising leads 
for the development of new antihypertensive agents. 
 
4. Experimental sections 
4.1. Chemistry 
1H NMR and 13C NMR spectra were recorded on a BrukerAV-300NMR, deuterated 
solvents were CDCl3, DMSO-d6 and MeOD-d4. Mass spectra were obtained on an 
Agilent 1100-LC-MSD-Traps/SL. All reagents and solvents were commercially 
available and used without further purification. Anhydrous DMF was obtained by 
distillation over CaH2 and anhydrous THF was obtained by distillation over Na. Silica 
gel 60 H (200-300 mesh), manufactured by Qingdao Haiyang Chemical Group Co., Ltd 
(China) was used for general chromatography. 
 
4.1.1 General procedure for the synthesis of compounds 13, 14 and 15.  
Isochroman-4-one was dissolved in anhydrous acetone, K2CO3 was added to the 
solution. Epichlorohydrin was added after refluxing under nitrogen for 30 min. The 
reaction was heated to reflux for 3 h. After completion of the reaction, the filtrate was 
collected by suctioning and spinning. The filtrate was diluted with ethyl acetate and 
washed twice with water. The organic layers were washed with saturated brine and 
dried over anhydrous sodium sulfate, the crude product was purified by column 
chromatography to give white solid in 75-82% yields. 
4.1.1.1. 
7-methoxy-3-methyl-6-(oxiran-2-ylmethoxy)isochroman-4-one (13) 
White solid; 1H NMR (CDCl3, 300 MHz) δ: 7.51 (s, 1H), 6.62 (s, 1H), 4.85 (s, 1H), 
4.33 (m, 1H), 4.24 (q, J = 6.7 Hz,1H), 4.03 (m, 1H), 3.93 (s, 3H), 3.40 (m, 1H), 2.92 
(m, 1H), 2.77 (m, 1H), 1.50 (d, J = 6.7 Hz, 3H); MS (ESI) m/z: 265.1 [M+H]+. 
4.1.1.2.  
6-methoxy-3-methyl-7-(oxiran-2-ylmethoxy)isochroman-4-one(14) 
White solid; 1H NMR (CDCl3, 300 MHz) δ: 7.50 (s, 1H), 6.68 (s, 1H), 4.85 (s, 2H), 
4.37 (m, 1H), 4.22 (q, J = 6.7 Hz, 1H), 4.05 (m, 1H), 3.92 (s, 3H), 3.41 (m, 1H), 2.93 
(m, 1H), 2.78 (m, 1H), 1.51 (d, J = 6.7 Hz, 3H); MS(ESI) m/z: 265.1 [M+H]+. 
4.1.1.3. 
7-methoxy-3-methyl-8-(oxiran-2-ylmethoxy)isochroman-4-one (15) 
White solid; 1H NMR (CDCl3, 300 MHz) δ: 7.83 (d, J = 8.7 Hz, 1H), 6.93 (d, J = 8.7 
Hz, 1H), 5.20 (q, J = 7.5 Hz, 1H), 4.82 (d, J = 15.7 Hz, 1H), 4.33 (m, 1H), 4.19 (q, J = 
6.7 Hz, 1H), 3.96 (s, 3H), 3.93 (m, 1H), 3.30 (m, 1H), 2.88 (m, 1H), 2.68 (m, 1H), 1.49 
(d, J = 6.7 Hz, 3H); MS (ESI) m/z: 265.1 [M+H]+. 
 
4.1.2 General procedure for the synthesis of compounds 6a-r. 
The above-mentioned epoxy compound (13-15), substituted piperazine and Zn(ClO4)2 
were mixed,dichloromethane was added, the reaction was heating to 80 ℃ in oil bath, 
The crude product was purified by column chromatography. The target compounds 6a-
f, 6g-l, 6m-r were white solid in 60-80% yields. 
 
4.1.2.1.  
6-(2-hydroxy-3-(4-phenylpiperazin-1-yl)propoxy)-7-methoxy-3-
methylisochroman-4-on (6a) 
1H-NMR (300 MHz, CDCl3) δ: 7.54 (s, 1H), 7.28 (m, 2H), 6.91 (m, 3H), 6.62 (s, 1H), 
4.88 (s, 2H), 4.26 (m, 2H), 4.11 (m, 2H), 3.94 (s, 3H), 3.27 (s, 4H), 2.91 (m, 2H), 2.75-
2.63 (m, 4H), 1.52 (d, J = 6.9 Hz, 3H); 13C-NMR (75 MHz, CDCl3) δ: 194.76, 154.56, 
151.17, 148.02, 137.42, 129.12, 122.40, 119.84, 116.12, 110.13, 106.21, 169.72, 154.36, 
147.79, 137.37, 122.19, 109.90, 106.18, 77.96, 71.85, 66.53, 65.71, 60.38, 56.12, 53.37, 
49.21, 15.86; HRMS (ESI) calcd for C24H31N2O5 [M + H]
+ 427.2227, found 427.2231. 
4.1.2.2.  
6-(2-hydroxy-3-(4-(2-methoxyphenyl)piperazin-1-yl)propoxy)-7-methoxy-3-
methylisochroman-4-one (6b) 
1H-NMR (300 MHz, CDCl3) δ: 7.39 (s, 1H), 7.11 (d, J = 7.8 Hz, 1H), 7.01 (m, 1H), 
6.84 (m, 2H), 6.51 (s, 1H), 4.77 (m, 2H), 4.11 (m, 3H), 3.94 (m, 3H), 3.81 (s, 3H), 3.78 
(s, 3H), 3.44-3.23 (m, 7H), 3.05 (m, 1H), 1.41 (d, J = 6.6 Hz, 3H); 13C-NMR (75 MHz, 
CDCl3) δ: 194.67, 158.42, 154.50, 148.01, 138.10, 137.31, 125.19, 123.96, 122.23, 
121.08, 111.83, 109.89, 106.17, 77.84, 71.47, 67.26, 66.47, 61.78, 57.36, 56.04, 55.38, 
51.33, 44.67, 42.79, 15.79; HRMS (ESI) calcd for C25H31N2O6Na2 [M-H+2Na]
+ 
501.1918, found 501.2232. 
4.1.2.3. 
6-(3-(4-(2-ethoxyphenyl)piperazin-1-yl)-2-hydroxypropoxy)-7-methoxy-3-
methylisochroman-4-one (6c) 
1H-NMR (300MHz, CDCl3) δ: 7.39 (s, 1H), 7.11 (d, J = 7.5 Hz, 1H), 7.00 (m, 1H), 
6.82 (m, 2H), 6.51 (s, 1H), 4.76 (m, 2H), 4.14-3.94 (m, 8H), 3.81 (s, 3H), 3.42 (q, J = 
8.1 Hz, 2H), 3.28 (m, 5H), 3.05 (m, 1H), 1.40 (m, 6H); HRMS (ESI) calcd for 
C26H33N2O6Na2 [M-H+2Na]
+ 515.2490, found 515.2401. 
4.1.2.4.  
6-(3-(4-(2-chlorophenyl)piperazin-1-yl)-2-hydroxypropoxy)-7-methoxy-3-
methylisochroman-4-one (6d) 
1H-NMR (300 MHz, CDCl3) δ: 7.46 (s, 1H), 7.38 (m, 1H), 7.32 (m, 1H), 7.23 (m, 1H), 
7.03 (m, 1H), 6.58 (s, 1H), 4.85 (m, 2H), 4.21 (m, 1H), 4.13-4.01 (m, 5H), 3.89 (s, 3H), 
3.55-3.21 (m, 7H), 1.50 (d, J = 6.69, 3H); HRMS (ESI) calcd for C24H28ClN2O5Na2 
[M-H+2Na]+ 505.1838, found 505.1744.  
4.1.2.5.  
6-(2-hydroxy-3-(4-(tetrahydrofuran-2-carbonyl)piperazin-1-yl)propoxy)-7-
methoxy-3-methylisochroman-4-one (6e) 
1H-NMR (300 MHz, CDCl3) δ: 7.39 (s, 1H), 6.52 (s, 1H), 4.75 (s, 2H), 4.51 (t, J = 5.7 
Hz, 1H), 4.11 (m, 2H), 3.98 (m, 2H), 3.9-3.7 (m, 5H), 3.60 (brs, 2H), 3.48 (brs, 2H), 
2.5 (m, 6H), 2.12 (m, 1H), 2.0-1.7 (m, 3H), 1.39 (d, J = 6.48 Hz, 3H); 13C-NMR (75 
MHz, CDCl3) δ: 194.60, 169.72, 154.36, 147.79, 137.37, 122.19, 109.90, 106.18, 75.63, 
71.74, 68.91, 66.36, 65.94, 60.36, 55.99, 53.64, 53.14, 53.00, 45.16, 41.78, 28.36, 25.56, 
15.72; HRMS (ESI) calcd for C23H33N2O7 [M+H]
+ 449.2288, found 449.2275. 
4.1.2.6.  
6-(3-(4-(furan-2-carbonyl)piperazin-1-yl)-2-hydroxypropoxy)-7-methoxy-3-
methylisochroman-4-one (6f) 
1H-NMR (300 MHz, CDCl3) δ: 7.45 (s, 1H), 7.43 (t, J = 0.78 Hz, 1H), 6.94 (d, J = 3.33 
Hz, 1H), 6.55 (s, 1H), 6.42 (t, J = 1.68 Hz, 1H), 5.25 (s, 2H), 4.16 (m, 2H), 4.12 (m, 
2H), 3.85 (s, 3H), 3.77 (brs, 4H), 3.43 (brs. 1H), 2.67 (m, 2H), 2.58 (m, 4H), 1.44 (d, J 
= 6.69 Hz, 3H); HRMS (ESI) calcd for C23H29N2O7 [M+H]
+ 445.1975, found 445.1977. 
4.1.2.7.  
7-(2-hydroxy-3-(4-phenylpiperazin-1-yl)propoxy)-6-methoxy-3-
methylisochroman-4-one (6g) 
1H-NMR (300 MHz, CDCl3) δ: 7.48 (s, 1H), 7.26 (t, J = 8.7 Hz, 2H), 6.99 (m, 3H), 
6.67 (s, 1H), 4.84 (m, 2H), 4.21 (m, 2H), 4.09 (m, 2H), 3.89 (s, 3H), 3.21 (m, 4H), 2.81 
(m, 2H), 2.62 (m, 4H), 1.50 (d, J = 6.66 Hz, 3H); 13C-NMR (75 MHz, CDCl3) δ: 
194.900, 153.344, 151.122, 149.086, 136.785, 129.150, 122.788, 119.926, 116.130, 
108.398, 107.643, 77.989, 71.717, 71.662, 66.496, 65.616, 60.388, 56.055, 53.361, 
49.245, 15.886; HRMS (ESI) calcd for C24H31N2O5 [M+H]
+ 427.2233, found 427.2228. 
4.1.2.8.  
7-(2-hydroxy-3-(4-(2-methoxyphenyl)piperazin-1-yl)propoxy)-6-methoxy-3-
methylisochroman-4-one (6h) 
1H-NMR (300 MHz, CDCl3) δ: 7.22 (s, 1H), 7.09 (d, J = 7.68 Hz, 1H), 7.00 (t, J = 7.74 
Hz, 1H), 6.82 (t, J = 7.38 Hz, 2H), 6.53 (s, 1H), 4.73 (m, 2H), 4.10 (m, 3H), 3.96 (m, 
3H), 3.76 (d, J = 3.6 Hz, 6H), 3.40-3.05 (m, 8H); 13C-NMR (75 MHz, CDCl3) δ: 
194.408, 158.054, 154.007, 152.907, 148.432, 136.385, 124.911, 123.630, 122.040, 
120.658, 114.407, 107.745, 107.049, 77.386, 70.934, 66.677, 65.914, 61.318, 56.610, 
55.468, 54.921, 50.957, 44.090, 42.056, 15.330; HRMS (ESI) calcd for C25H31N2O6Na2 
[M-H+2Na]+ 501.1978, found 501.2242. 
4.1.2.9.  
7-(3-(4-(2-ethoxyphenyl)piperazin-1-yl)-2-hydroxypropoxy)-6-methoxy-3-
methylisochroman-4-one (6i) 
1H-NMR (300 MHz, CDCl3) δ: 7.36 (s, 1H), 7.10 (d, J = 7.71 Hz, 1H), 6.99 (t, J = 6.5 
Hz, 1H), 6.80 (t, J = 7.59 Hz, 2H), 6.54 (s, 1H), 4.72 (m, 2H), 4.13-3.94 (m, 8H), 3.76 
(s, 3H), 3.10-3.04 (m, 7H), 3.07 (m, 1H), 1.38 (m, 6H); 13C-NMR (75 MHz, CDCl3) δ: 
194.4, 158.0, 153.56, 152.95, 148.49, 136.34, 125.08, 124.14, 122.05, 120.49, 112.10, 
107.74, 107.09, 77.38, 70.91, 66.65, 65.94, 63.23, 61.27, 57.02, 55.45, 50.87, 44.10, 
42.14, 15.33, 14.32; HRMS (ESI) calcd for C26H33N2O6Na2 [M-H+2Na]
+ 515.2134, 
found 515.2397. 
4.1.2.10.  
7-(3-(4-(2-chlorophenyl)piperazin-1-yl)-2-hydroxypropoxy)-6-methoxy-3-
methylisochroman-4-one (6j) 
1H-NMR (300 MHz, CDCl3) δ: 7.46 (s, 1H), 7.38 (m, 1H), 7.32 (m, 1H), 7.21 (m, 1H), 
7.05 (m, 1H), 6.60 (s, 1H), 4.82 (s, 2H), 4.21 (m, 1H), 4.14-4.02 (m, 5H) , 3.87 (s, 3H), 
1.50 (d, J = 6.69 Hz, 3H), 3.50-3.27 (m, 8H); 13C-NMR (75 MHz, CDCl3) δ: 194.93, 
158.49, 153.22, 148.91, 146.71, 136.88, 130.77, 127.73, 125.57, 125.06, 122.65, 
108.27, 107.63, 77.92, 71.30, 67.37, 66.42, 61.74, 55.99, 54.95, 51.45, 44.30, 42.23, 
15.84; HRMS (ESI) calcd for C24H28ClN2O5Na2 [M-H+2Na]
+ 505.1482, found 
505.1747. 
4.1.2.11.  
7-(2-hydroxy-3-(4-(tetrahydrofuran-2-carbonyl)piperazin-1-yl)propoxy)-6-
methoxy-3-methylisochroman-4-one (6k) 
1H-NMR (300 MHz, CDCl3) δ: 7.39 (s, 1H), 6.58 (s, 1H), 4.77 (m, 2H), 4.50 (t, J = 5.7 
Hz, 1H), 4.30 (m, 2H), 4.02 (m, 2H), 3.9-3.7 (m, 5H), 3.65 (s, 4H), 2.4-2.6 (m, 6H), 
2.17 (m, 1H), 1.90 (m, 3H), 1.43 (d, J = 6.66 Hz, 3H); 13C-NMR (75 MHz, CDCl3) δ: 
194.31, 169.29, 152.69, 148.46, 136.29, 122.25, 107.86, 107.13, 77.40, 75.27, 71.09, 
68.53, 65.89, 65.27, 59.89, 55.48, 44.68, 41.32, 27.85, 25.16, 15.30; HRMS (ESI) calcd 
for C23H33N2O7 [M+H]
+ 449.2288, found 449.2285. 
4.1.2.12  
7-(3-(4-(furan-2-carbonyl)piperazin-1-yl)-2-hydroxypropoxy)-6-methoxy-3-
methylisochroman-4-one (6l) 
1H-NMR (300 MHz, CDCl3) δ: 7.39 (d, J = 5.16 Hz, 2H), 6.92 (d, J = 3.27 Hz, 1H), 
6.58 (s, 1H), 6.4 (t, J = 1.56 Hz, 1H), 4.75 (s, 2H), 4.15 (m, 2H), 4.12 (m, 2H), 3.84 (m, 
7H), 2.55 (m, 6H), 1.41 (d, J = 6.66 Hz, 3H); 13C-NMR (75 MHz, CDCl3) δ: 194.32, 
158.50, 152.70, 148.48, 147.19, 143.28, 136.29, 122.27, 116.10, 110.82, 107.88, 107.16, 
77.41, 71.10, 65.90, 65.32, 59.90, 55.49, 52.99, 15.32; HRMS (ESI) calcd for 
C23H29N2O7 [M+H]
+ 445.1975, found 445.1979. 
4.1.2.13.  
8-(2-hydroxy-3-(4-phenylpiperazin-1-yl)propoxy)-7-methoxy-3-
methylisochroman-4-one (6m) 
1H-NMR (300 MHz, CDCl3) δ: 7.85 (d, J = 8.7 Hz, 1H), 7.28 (m, 2H), 6.94 (d, J = 
8.28 Hz, 3H), 6.88 (t, J = 7.27 Hz, 1H), 5.25 (m, 1H), 4.84 (m, 1H), 4.20 (q, J = 6.6 
Hz, 1H), 4.17-3.97 (m, 3H), 3.95 (s, 3H), 3.22 (m, 4H), 2.85 (m, 2H), 2.69-2.54 (m, 
4H), 1.51 (d, J = 6.6 Hz, 3H); 13C-NMR (75 MHz, CDCl3) δ: 194.93, 156.54, 151.15, 
136.08, 129.14, 124.16, 123.23, 119.91, 116.14, 111.08, 77.75, 75.43, 75.30, 66.29, 
66.25, 62.91, 60.19, 55.92, 53.38, 49.26, 15.68; HRMS (ESI) calcd for C24H31N2O5 
[M+H]+ 427.2233, found 427.2223. 
4.1.2.14.  
8-(2-hydroxy-3-(4-(2-methoxyphenyl)piperazin-1-yl)propoxy)-7-methoxy-3-
methylisochroman-4-one (6n) 
1H-NMR (300 MHz, CDCl3) δ: 7.72 (d, J = 8.4 Hz, 1H), 7.10 (d, J = 7.5 Hz, 1H), 7.03 
(m, 1H), 6.85 (m, 3H), 5.08 (d, J = 15.6 Hz, 1H), 4.68 (m, 1H), 4.06 (m, 3H), 3.92 (m, 
3H), 3.81 (s, 3H), 3.78 (s, 3H), 3.41-3.26 (m, 7H), 3.02 (m, 1H), 1.39 (d, J = 6.6 Hz, 
3H); 13C-NMR (75 MHz, CDCl3) δ: 194.43, 158.02, 156.02, 154.09, 141.74, 135.49, 
125.01, 123.75, 123.44, 122.155, 120.65, 111.39, 110.56, 77.09, 74.69, 74.57, 67.29, 
62.33, 61.33, 56.97, 55.35, 54.94, 50.90, 44.09, 42.02, 15.11; HRMS (ESI) calcd for 
C25H31N2O6Na2 [M-H+2Na]
+ 501.1978, found 501.2242. 
4.1.2.15.  
8-(3-(4-(2-ethoxyphenyl)piperazin-1-yl)-2-hydroxypropoxy)-7-methoxy-3-
methylisochroman-4-one (6o) 
1H-NMR (300 MHz, CDCl3) δ: 7.73 (d, J = 8.7 Hz, 1H), 7.12 (d, J = 7.5 Hz, 1H), 7.02 
(t, J = 7.56 Hz, 1H), 6.84 (m, 3H), 5.10 (d, J = 15.6 Hz, 1H), 4.68 (m, 1H), 4.11-3.85 
(m, 6H), 3.82 (s, 3H), 3.44-3.27 (m, 7H), 3.03 (m, 1H), 1.41-1.36 (m, 6H); 13C-NMR 
(75 MHz, CDCl3) δ: 194.46, 156.06, 153.68, 141.77, 135.52, 125.06, 124.19, 123.47, 
122.57, 120.50, 112.08, 110.54, 77.12, 74.67, 74.54, 67.33, 67.28, 63.24, 62.34, 61.27, 
57.30, 55.35, 50.81, 44.10, 42.14, 15.12, 14.34; HRMS (ESI) calcd for C26H33N2O6Na2 
[M-H+2Na]+ 515.2134, found 515.2401. 
4.1.2.16.  
8-(3-(4-(2-chlorophenyl)piperazin-1-yl)-2-hydroxypropoxy)-7-methoxy-3-
methylisochroman-4-one (6p) 
1H-NMR (300 MHz, CDCl3) δ: 7.82 (d, J = 8.67 Hz, 1H), 7.38 (m, 2H), 7.25 (m, 1H), 
7.06 (m, 1H), 6.92 (d, J = 8.7 Hz, 1H), 5.15 (m, 1H), 4.76 (m, 1H), 4.19-4.03 (m, 6H), 
3.99-3.88 (d, J = 5.97 Hz, 3H), 3.56-3.22 (m, 8H), 1.48 (d, J = 6.69 Hz, 3H) ; 13C-
NMR (75 MHz, CDCl3) δ: 194.94, 158.43, 156.47, 146.70, 142.14, 142.04, 136.03, 
130.77, 127.72, 125.55, 125.18, 124.13, 123.10, 111.02, 77.66, 75.19, 75.02, 68.01, 
67.94, 62.80, 61.74, 55.90, 55.12, 51.11, 44.30, 42.22, 29.67, 15.64; HRMS (ESI) calcd 
for C24H28ClN2O5Na2 [M-H+2Na]
+ 505.1482, found 505.1745. 
4.1.2.17.  
8-(2-hydroxy-3-(4-(tetrahydrofuran-2-carbonyl)piperazin-1-yl)propoxy)-7-
methoxy-3-methylisochroman-4-one (6q) 
1H-NMR (300 MHz, CDCl3) δ: 7.74 (d, J = 8.64 Hz, 1H), 6.86 (d, J = 8.67 Hz, 1H), 
5.15 (m, 1H), 4.76 (m, 1H), 4.53 (t, J = 5.88 Hz, 1H), 4.10 (m, 1H), 4.01-3.73 (m, 8H), 
3.63 (s, 2H), 3.52 (s, 2H), 2.50 (m, 6H), 2.18 (m, 1H), 1.93 (m, 3H), 1.40 (d, J = 6.60 
Hz, 3H); 13C-NMR (75 MHz, CDCl3) δ: 194.86, 169.84, 156.47, 142.08, 135.99, 124.18, 
123.15, 111.08, 77.68, 75.78, 75.30, 75.18, 69.05, 66.40, 66.35, 62.83, 60.21, 55.91, 
45.22, 41.85, 28.39, 25.67, 15.62; HRMS (ESI) calcd for C23H33N2O7 [M+H]
+ 449.2288, 
found 449.2277. 
4.1.2.18.  
8-(3-(4-(furan-2-carbonyl)piperazin-1-yl)-2-hydroxypropoxy)-7-methoxy-3-
methylisochroman-4-one (6r) 
1H-NMR (300 MHz, CDCl3) δ: 7.73 (d, J = 8.37 Hz, 1H), 7.41 (s, 1H), 6.92 (s, 1H), 
6.85 (d, J = 8.37 Hz, 1H), 6.4 (s, 1H), 5.15 (d, J = 4.68 Hz, 1H), 5.11 (d, J = 4.29 Hz, 
1H), 4.2-3.9 (m, 4H), 3.84 (s, 3H), 3.76 (brs, 4H), 2.49 (brs, 4H), 1.39 (d, J = 6.03 Hz, 
3H); 13C-NMR (75 MHz, CDCl3) δ: 194.85, 159,01, 156.47, 147.69, 143.78, 142.08, 
141.97, 135.99, 128.74, 124.14, 123.12, 116.56, 111.30, 111.08, 77.66, 75.34, 75.22, 
66.50, 66.44, 62.82, 60.21, 55.90, 53.49, 15.61; HRMS (ESI) calcd for C23H29N2O7 
[M+H]+ 445.1975, found 445.1970. 
 
4.2. Pharmacological evaluation 
4.2.1. Vasodilatory activity in thoracic aorta  
Male Sprague-Dawley rats (SD rats;180-200g body weight ) were narcotized by 
intraperitoneal injection of sodium pentobarbitone (60 mg/mL). The thoracic aorta was 
quickly excised and the connective and adipose tissues were cleaned from the vessel 
before it was cut into 4 mm segments , which were suspended in 10 mL organ baths. 
The baths were filled with gassed (5% CO2 and 95% O2) Tyrode’s solution (in mmol/L: 
NaCl 112.2; KCl 5.0; CaCl2 2.5; MgSO4 1.2; KH2PO4 1.0; NaHCO3 12.0; glucose 11.1) 
and warmed to 37 ℃. The aortic rings were tensioned to 1.0g and allowed toequilibrate 
for 1 h.The isometric tension was recorded using a Powerlab 400TM data acquisition 
system (software Chart, version 7.0, AD Instruments, MA, USA). The preparation was 
allowed toequilibrate for at least 60 min prior to initiation of experimental procedures, 
and during this period, the incubation media was changed every 15 min. After 
equilibration, the tissues were contracted twice by NA (1μM). When the contractions 
werestable, compound was added in progressively increasing cumulative 
concentrations (10-8-10-4M) at 30 min intervals. Data are expressed as mean ± S.E.M. 
The compounds were dissolved in DMSO. DMSO had no effect on NE-contractile 
response. 
 4.2.2. The blocking activity (pA2) of representative compounds 
The blocking activity (pA2) of compound 6e, 6f, 6g, 6h, 6m and 6q was measured by 
using the methods similar to those described previously. Male rats (SPF rats; 200-250 
g) were euthanasia by intraperitoneal injection of sodium pentobarbitone. The required 
organs were rapidly isolated and placed in Kreb’s solution of the following composition 
(mM): NaCl 112.2; KCl 5.0; CaCl2 2.5; MgSO4 1.2; KH2PO4 1.0; NaHCO3 12.0; 
glucose 11.1; respectively. After excess of fat and connective tissue was removed, the 
tissues were set up rapidly, under a suitable resting tension (vas thoracic aorta 1.0 g) in 
10-mL organ baths containing Kreb’s solution kept at 37 ℃ and aerated with 5% CO2: 
95% O2 at PH 7.4. Isolated vascular ring strips were denuded of endothelium to avoid 
any complicating effects of endothelium-derived factors. After equilibration for 1h in 
the Krebs solution, concentration-response curves were constructed by cumulative 
addition of agonist NA. The concentration of NA in the organ bath was increased 
approximately three-fold at each step, with each addition being made only after the 
response to the previous addition had attained a maximal level and remained steady. 
The first concentrations-response curve was the basic one, and the other two with NA 
were repeated by adding testing compounds and naftopidil respectively. The individual 
tissues were exposed to only one tested antagonist. The pA2 values of each compound 
were calculated from the following equation: pA2= -log (B) + log (r-1), where (B) is the 
molar concentration of antagonists, and r is the ratio of agonist EC50 determined in the 
presence and absence of antagonist . 
 
4.2.3. Antihypertensive effects in SHRs 
Male SHRs were purchased from Vital River Laboratory Animal Technology Co. Ltd 
(Beijing, China). After one week of acclimation, 30 SHRs (200-250 g body weight) 
were randomly divided into 3 groups, namely the control group, captopril control group 
and the compounds 6egroups. After oral administration with saline water, captopril (80 
mg/kg) and 6e (80 mg/kg) to SHRs respectively, the SAP, DAP and heart rate (HR) 
were measured using the tail-cuff method with a blood pressure monitor (BP-2000, 
Visitech Systems, Inc., US) from 0 to 8h. 
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